Don’t let the high cost of brand dihydroergotamine autoinjector disrupt your migraine treatment. We help eligible patients access Brekiya (dihydroergotamine mesylate autoinjector) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Brekiya Patient Assistance Program helps eligible patients access this dihydroergotamine autoinjector at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Brekiya PAP enrollment for a flat $69.95 per month — so you never face a gap in your Brekiya migraine therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Brekiya enrollment — so you never face a gap in your acute migraine treatment.
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Sumatriptan generic (alt) | ~$15/tab | Cheap generic triptan alt |
| Walgreens | ~$1,100/dose | Save substantially |
| CVS Pharmacy | ~$1,200/dose | Save substantially |
| Walmart | ~$900/dose | Save substantially |
| Specialty pharmacy | ~$800/dose | Save substantially |
| Trudhesa (nasal DHE alt) | ~$1,000/dose | Alt DHE nasal spray |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Brekiya — independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Brekiya Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Generic triptans are very cheap alternatives for most migraines. Brekiya’s DHE mechanism is appropriate for status migrainosus, triptan-resistant migraine, cluster headache, or patients with cardiovascular contraindications to triptans (though ergots also carry vasoconstrictive risk — careful patient selection).
Complete a simple eligibility form so our team can determine if you may qualify for Brekiya assistance.
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Once approved, your Brekiya is delivered through the assistance program while we manage refills and annual renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Brekiya:
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $800–$1,200/dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Fixed $69.95/month — never changes regardless of retail price
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Brekiya assistance.
Brekiya is the first dihydroergotamine autoinjector — enabling patient-administered subcutaneous DHE at home. DHE is effective for acute migraine and cluster headache but was historically limited to IV/IM (medical settings) or nasal spray. Autoinjector delivery expands access.
How It Works:
Migraine and cluster headache are severe primary headache disorders with distinct triggers, symptoms, and treatment approaches. Acute treatment aims for rapid, complete headache relief with minimal side effects; preventive treatment is for frequent or severe episodes. Dihydroergotamine (DHE) is a serotonin (5-HT1B/D) receptor agonist with additional adrenergic and dopaminergic effects — effective for migraine and cluster headache. Historically limited by IV/IM formulation. Trudhesa introduced improved nasal delivery. Brekiya is the first autoinjector — patient-administered SC delivery expands access.
Form and Use:
Brekiya autoinjector for subcutaneous administration. Single-use pen. May be repeated per prescribing information for persistent or recurrent headache. Training provided by prescriber. Take at the first sign of a migraine or cluster attack.
Generic Availability:
No generic Brekiya. Other DHE: Migranal (DHE nasal spray — brand), Trudhesa (improved DHE nasal spray — brand), IV/IM DHE (generic — medical settings). Triptans: sumatriptan (generic — oral, injectable, nasal), rizatriptan (generic), zolmitriptan (generic), naratriptan, almotriptan, frovatriptan, eletriptan — all generic and cheap. CGRP-targeted therapies: Ubrelvy (ubrogepant), Nurtec ODT (rimegepant — acute and prevention), Zavzpret (zavegepant nasal). CGRP mAbs for prevention: Ajovy, Emgality, Aimovig, Vyepti. Preventive options: Botox (chronic migraine), CGRP mAbs, topiramate generic, propranolol generic, TCAs, valproate, verapamil (cluster prevention). American Migraine Foundation resources.
Warnings:
Serious cardiovascular events (contraindicated in coronary artery disease, uncontrolled hypertension, peripheral vascular disease, sepsis, pregnancy — vasoconstrictive), contraindicated with strong CYP3A4 inhibitors (potent macrolides, azoles, protease inhibitors — risk of severe peripheral ischemia), medication overuse headache (limit use), fibrotic complications with prolonged use (historical concern with chronic ergot use). Other: injection site reactions, nausea, vomiting, muscle cramps, chest tightness. Cardiovascular risk assessment before starting. Not for hemiplegic or basilar migraine.
$800–$1,200 per autoinjector at retail pharmacies. Generic sumatriptan (oral tablets or injectable) costs $10–$50 with GoodRx — a vastly cheaper alternative for most migraines. Nurtec ODT (rimegepant — brand acute + prevention gepant) costs $800–$1,000/month at specialty pharmacy.
Adults with acute migraine (with or without aura) and acute cluster headache. Especially useful for status migrainosus (severe prolonged migraine), triptan-resistant or triptan-intolerant migraine, and cluster headache attacks. Not for patients with cardiovascular disease (contraindicated — vasoconstriction). Careful patient selection.
Brekiya is the first DHE autoinjector — patient-administered SC at home. Historical DHE was IV/IM (requires medical setting) or nasal spray (Migranal and Trudhesa). The autoinjector combines DHE efficacy with home administration — expanding access and avoiding ED visits for severe migraine or cluster attacks.
Both are 5-HT1B/D receptor agonists effective for acute migraine. Triptans (mostly generic and cheap) are first-line for most acute migraine. DHE has broader receptor activity, longer duration, and is particularly effective for status migrainosus, triptan-resistant migraine, and cluster headache — but has more vasoconstrictive potential and more CYP3A4 drug interactions. Careful cardiovascular patient selection.
Do not combine with triptans within 24 hours (additive vasoconstriction). Do not use with strong CYP3A4 inhibitors (potent macrolides, azoles, protease inhibitors) — risk of severe peripheral ischemia. Discuss all medications with your prescriber, including antibiotics.
Severe migraine and cluster headache can be disabling — accessible acute therapy matters. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.